Merck’s MF/F Phase III study data presented at AAAAI annual meeting
Categories: Uncategorized
Posted on: 3rd March 2010 by: admin
Posted on: 3rd March 2010 by: admin
Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma Immunology (AAAAI) annual meeting. Continue Reading
